Impact of quetiapine on resolution of individual delirium symptoms in critically ill patients with delirium: a post-hoc analysis of a double-blind, randomized, placebo-controlled study

Table 2 Proportion of patients experiencing resolution and time to first resolution for the delirium symptoms^A

	Resolved during therapy^AN (%)			Time to first resolution^A (hours; median (IQR))
Delirium symptoms derived from ICDSC	Quetiapine ( n = 14)	Placebo ( n = 15)	^BP -value	Quetiapine ( n = 14)	Placebo ( n = 15)	^CP -value
Agitation	5 (100.0)	6 (100.0)	-	84 (48 to 204)	36 (24 to 60)	0.07
Decreased level of consciousness	5 (83.3)	6 (100.0)	0.30	36 (24 to 72)	24 (12 to 96)	0.78
Inattention	12 (92.3)	11 (73.3)	0.19	84 (24 to 168)	180 (72 to 240)	0.12
Disorientation	11 (85.6)	8 (72.7)	0.47	48 (12 to 216)	204 (36 to 240)	0.10
Hallucinations/delusions	2 (100.0)	1 (100.0)	-	48 (24 to 72)	156 (144 to 156)	0.22
Hyperactivity	5 (100.0)	6 (100.0)	-	120(60 to 192)	24 (12 to 48)	0.04
Hypoactivity	7 (77.8)	6 (66.7)	0.60	72 (48 to 132)	168 (96 to ne)	0.17
Inappropriate speech or mood	6 (85.7)	3 (100.0)	0.49	132(60 to 192)	72 (24 to 168)	0.31
Sleep/wake cycle disturbance	5 (62.5)	6 (60.0)	0.91	192 (24 to ne)	228 (144 to 240)	0.36
Symptom fluctuation	11 (100.0)	7 (53.8)	0.009	4 (1 to 10)	14 (7 to ne)	0.004

ICDSC, Intensive Care Delirium Screening Checklist
IQR, Interquartile range expressed as 25th to 75th percentile; the value of "ne" indicates the value could not be estimated from these
^BP-value from comparison of proportion resolved between the two groups using the Pearson's Chi-square test.
^CP-value from comparison of time to first resolution between the two groups from Log-Rank test comparing Kaplan-Meier curves

ISSN: 1364-8535